Janssen Sciences Ireland UC

4 articles about Janssen Sciences Ireland UC

• CinFina Pharma In-Licenses Obesity Portfolio

  9/22/2021

  CinFina Pharma, LLC. announced that it has signed an agreement with Janssen Sciences Ireland Unlimited Company, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to acquire exclusive global rights to GDF-15 and PYY analogs and GLP-1/GDF-15 and GLP/PYY dual agonists.

• 

  ViiV Healthcare Announces 3-Year HIV Data for Juluca 2-Drug Combo

  4/3/2019

  ViiV Healthcare, presented three-year data from the SWORD 1 and 2 clinical trials in HIV. The data was presented at the 25th Annual Conference of the British HIV Association (BHIVA) in Bournemouth, UK.

• EUSA Pharma Announces Acquisition of Global Rights to SYLVANT® (siltuximab) from Janssen Sciences Ireland UC for $115 Million

  7/18/2018

  Acquisition significantly boosts EUSA Pharma’s presence as a global biopharmaceutical company in oncology and rare disease

• Janssen Sciences Ireland UC Releases: Data Published In Lancet Shows High Efficacy At 96 Weeks For First Investigational Two-Drug, Long-Acting Injectable HIV Regimen

  7/24/2017